European stroke organisation (ESO) guideline on cerebral small vessel disease, part 2, lacunar ischaemic stroke

Joanna M Wardlaw*, Hugues Chabriat, Frank-Erik de Leeuw, Stéphanie Debette, Martin Dichgans, Fergus Doubal, Hanna Jokinen, Aristeidis H Katsanos, Raffaele Ornello, Leonardo Pantoni, Marco Pasi, Aleksandra M Pavlovic, Salvatore Rudilosso, Reinhold Schmidt, Julie Staals, Martin Taylor-Rowan, Salman Hussain, Arne G Lindgren

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

A quarter of ischaemic strokes are lacunar subtype, typically neurologically mild, usually resulting from intrinsic cerebral small vessel pathology, with risk factor profiles and outcome rates differing from other stroke subtypes. This European Stroke Organisation (ESO) guideline provides evidence-based recommendations to assist with clinical decisions about management of lacunar ischaemic stroke to prevent adverse clinical outcomes. The guideline was developed according to ESO standard operating procedures and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. We addressed acute treatment (including progressive lacunar stroke) and secondary prevention in lacunar ischaemic stroke, and prioritised the interventions of thrombolysis, antiplatelet drugs, blood pressure lowering, lipid lowering, lifestyle, and other interventions and their potential effects on the clinical outcomes recurrent stroke, dependency, major adverse cardiovascular events, death, cognitive decline, mobility, gait, or mood disorders. We systematically reviewed the literature, assessed the evidence and where feasible formulated evidence-based recommendations, and expert concensus statements. We found little direct evidence, mostly of low quality. We recommend that patients with suspected acute lacunar ischaemic stroke receive intravenous alteplase, antiplatelet drugs and avoid blood pressure lowering according to current acute ischaemic stroke guidelines. For secondary prevention, we recommend single antiplatelet treatment long-term, blood pressure control, and lipid lowering according to current guidelines. We recommend smoking cessation, regular exercise, other healthy lifestyle modifications, and avoid obesity for general health benefits. We cannot make any recommendation concerning progressive stroke or other drugs. Large randomised controlled trials with clinically important endpoints, including cognitive endpoints, are a priority for lacunar ischaemic stroke.
Original languageEnglish
Article number23969873231219416
Pages (from-to)5-68
Number of pages64
JournalEuropean Stroke Journal
Volume9
Issue number1
Early online date21 Feb 2024
DOIs
Publication statusPublished - Mar 2024

Keywords

  • Guideline
  • alteplase
  • antihypertensive
  • antiplatelet
  • lacunar stroke
  • lipid lowering
  • small vessel disease
  • stroke
  • systematic review
  • thrombolysis

Cite this